Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01028404 | A Two Part Trial Investigating NN1952 in Healthy Subjects and Subjects With Type 1 and Type 2 Diabetes | PHASE1 | COMPLETED | 84 | — | — | Nov 1, 2009 | Jun 1, 2010 | Jul 25, 2017 | 1 | Germany |
| Arm | Type | Description |
|---|---|---|
| Trial part 1 | EXPERIMENTAL | - |
| Trial part 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| NN1952 | DRUG | Subjects will be randomised to receive a single dose of NN1952, at escalating dose levels. Progression to next dose will be based on safety evaluation. |
| insulin aspart | DRUG | As an active comparator, one standard dose will be given s.c. (under the skin) at all dose levels. |
| placebo | DRUG | Subjects will receive a single dose of placebo as a comparator to NN1952, at all dose levels. |
Inclusion Criteria: * FOR TRIAL PART 1, THE FOLLOWING APPLIES: * Gender: male * Age: 18-55 years * BMI (body mass index): 18-28 kg/m2 * Study participants considered to be healthy * FOR TRIAL PART 2, THE FOLLOWING APPLIES: * Gender: male or female of no childbearing potential * Age: 18-65 years * T...